Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seagen Inc

< Previous 1 2 3 4 5 Next >
Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
From Seagen Inc.
Via Business Wire
3 Stocks Worth Buying at 52-Week Lows
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors 
Via MarketBeat
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
Seagen Stockholders Approve Acquisition by Pfizer
From Seagen Inc.
Via Business Wire
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Seagen Reports First Quarter 2023 Financial Results
From Seagen Inc.
Via Business Wire
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
From Kahn Swick & Foti, LLC
Via Business Wire
Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
From Seagen Inc.
Via Business Wire
SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
From Seagen Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. (NYSE - UNVR), Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), U.S. Xpress Enterprises, Inc. (NYSE – USX)
From Brodsky & Smith LLC
Via GlobeNewswire
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later 
Via MarketBeat
MarketBeat Week in Review – 3/13 - 3/17
The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock 
Via MarketBeat
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
From Seagen Inc.
Via Business Wire
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Pfizer Invests $43 Billion to Battle Cancer
From Seagen Inc.
Via Business Wire
Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen to Present at the Cowen 43rd Annual Health Care Conference
From Seagen Inc.
Via Business Wire
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
From Seagen Inc.
Via Business Wire
Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Seagen Inc.
Via Business Wire
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
From Seagen Inc.
Via Business Wire
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.